BioArctic is a research-intensive biopharmaceutical company developing disease-modifying antibody treatments for neurodegenerative diseases. The company focuses on Alzheimer's disease, Parkinson's disease, Lewy body dementia, multiple system atrophy, amyotrophic lateral sclerosis (ALS), and Huntington's disease. Its pipeline includes lecanemab, marketed as Leqembi by partner Eisai, and exidavnemab for Parkinson's-related conditions. BioArctic utilizes its proprietary BrainTransporter technology to facilitate the passage of biologics across the blood-brain barrier. Key partnerships include a long-term collaboration with Eisai for the development and co-promotion of lecanemab in the Nordic region, a global licensing agreement with Bristol Myers Squibb for amyloid-beta projects, and a 2025 options and license agreement with Novartis. The company was founded in 2003 by Lars Lannfelt and Pär Gellerfors.

Summarised from the company's own disclosures, fiscal year ended Dec 2025

Industry Biotechnology Homepage bioarctic.se
Sector Healthcare IR page bioarctic.com/en/investors
Tags
neurodegenerative diseases, antibody therapeutics, blood-brain barrier, alzheimer's disease, parkinson's disease, als, huntington's disease, amyloid-beta, alpha-synuclein, tdp-43, lecanemab, Leqembi, exidavnemab, BrainTransporter, BAN1503, BAN2803, BAN2802, BAN2238, PD-BT2278, BAN3014, ND-BT3814, HD-BT4801
Press page bioarctic.com/en/media/press-releases

Metrics

Valuation  
Market cap kr 23.671B
Market cap (USD) $ 2.33B
P/E 18.80
PEG —
P/BV 14.30
P/S 379.67
P/OCF 16.54
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE 88.0%
ROI 64.0%
ROIC 52.1%
Profit margin 63.0%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 83
Quality score 35.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016
Revenue 1.999B 257.352M 615.995M 228.291M 23.146M 62.347M 281.772M 713.97M 140.706M 105.613M
Net profit 1.259B -228.515M 252.64M -17.442M -139.723M -68.517M 88.468M 381.602M 15.157M 57.58M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016
Share price 310.8 199.5 267.8 272 10.5 — 94.9 — — —
Price performance 12m 0.56 -0.26 -0.02 24.9 -0.89 — — — — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (SEK) — 0.00 2.84M 0.00 223,000 71.2M 122M
↳ YoY growth -100.0% +31,826.5% +70.9%
Other receivables (SEK) — 4.26M 4.65M 6.74M 6.88M 35.6M 21.3M
Lease liabilities (SEK) — 20.8M 15.9M 10M 4.98M 54.2M 44.1M
Cash and deposits (SEK) 1.11B 1,000M 848M 805M 612M 513M 1.04B
Right-of-use assets (SEK) — 21.8M 16.8M 11.7M 7.59M 57.2M 46.1M
Cash flow detail
Purchases of property, plant and equipment (SEK) — -12.5M -4.39M -12.7M -7.44M -26.6M -10.2M
Change in receivables (cash effect) (SEK) — 23.1M -5.12M -2.41M -12M -105M -64.8M
Change in payables (cash effect) (SEK) — 3.47M 62,000 27.3M 25.1M 42.7M 239M
Dividends paid (cash effect) (SEK) — 0.00 0.00 -5.99M -15M -6.02M -26M
Interest paid (cash effect) (SEK) — -1.69M -984,000 -751,000 -379,000 -1.85M -2.35M
Income taxes paid (cash effect) (SEK) — 12.2M 309,000 340,000 156,000 -520,000 -71.6M
Income detail
Research and development expense (SEK) — — — — 172M 311M 377M
Total comprehensive income (SEK) — 68.5M 120M 11.2M 229M -177M 1.02B
Comprehensive income to owners (SEK) — -68.5M -120M -11.2M 229M -177M 1.02B
Reported — — — — — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

First patient treated with Leqembi® (lecanemab) in Sweden Bull 2 Bear 0 Product/operations

September 22, 2026 16:10 Non Regulatory

Stockholm, Sweden, September 22, 2026 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that Leqembi is now available at a private clinic in Sweden and that the first patient has started treatment. This is the first time a patient in Sweden has been treated outside of a clinical study since Leqembi received EU approval in April 2025.

“I am very happy that we are now starting to help people diagnosed with early Alzheimer’s disease in Sweden as well. There is a significant unmet need for new treatment options that slow the progression of Alzheimer’s disease from its early stages and reduce the overall burden for patients affected by the disease, their care partners, healthcare providers and society,” said Gunilla Osswald, CEO of BioArctic. “It is great to see that this innovation, based on Professor Lars Lannfelt’s research at Uppsala University, is finally, after more than 20 years of research and development, beginning to help patients in Sweden, where it all started.”

Leqembi was approved in the EU in April 2025 as the first therapy that targets an underlying cause of Alzheimer’s disease (AD). It is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment (MCI) and mild dementia due to AD (early AD) who are apolipoprotein E ε4 (ApoE ε4[1] ) non-carriers or heterozygotes with confirmed amyloid pathology.[2]

Following the EU approval, Eisai and BioArctic have worked to enable patient access in Sweden. However, in April 2026, the New Therapies Council, NT-rådet, gave a negative recommendation for inclusion of Leqembi in the publicly funded health care system. Following NT-rådet’s recommendation, Executive Health in Stockholm, where the first patient was treated today, has been working to offer treatment to patients with early Alzheimer’s disease.

Leqembi is the result of a long-standing collaboration between BioArctic and Eisai, and the antibody was originally developed by BioArctic based on the work of Professor Lars Lannfelt and his discovery of the Arctic mutation in Alzheimer’s disease. Eisai is responsible for the clinical development, applications for regulatory approval and global commercialization of Leqembi for Alzheimer’s disease. BioArctic has the right to commercialize Leqembi in the Nordic region together with Eisai.

—

The information was released for public disclosure, through the agency of the contact person below, on September 22, 2026, at 4:10 pm CEST.
 

Leqembi® Pen subcutaneous formulation approved in Japan Bull 5 Bear 0 Clinical/regulatory

September 16, 2026 08:05 Regulatory

Stockholm, Sweden, September 16, 2026 – BioArctic AB (publ)’s (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the subcutaneous autoinjector formulation of Leqembi (known as Leqembi Pen in Japan) has been approved as a new route of administration for the treatment of early Alzheimer’s disease.

Leqembi Pen enables patients or care partners to self-administer treatment, with two injections (totaling 500 mg) given once weekly. This approval in Japan provides people living with early Alzheimer’s disease with an additional treatment option, allowing once-weekly subcutaneous administration at home[1] , complementing the existing intravenous (IV) formulation, which is administered every two weeks in a hospital setting.

Leqembi Pen may reduce the time required for treatment administration compared with IV infusions, with each injection taking approximately 15 seconds. The option for at-home administration may reduce the burden of clinic visits for patients and their care partners and provide a treatment option that better fits their lifestyles. 

The subcutaneous treatment option is expected to lower barriers to initiating and continuing treatment and has the potential to reduce healthcare resources associated with IV administration, such as nurse monitoring and maintaining infusion capacity. This may help streamline the overall Alzheimer’s disease treatment pathway.

As with IV administration, monitoring for ARIA (amyloid-related imaging abnormalities) involves brain magnetic resonance imaging (MRI) before treatment is initiated and at specified time points thereafter.

Japan is the third country globally to approve the subcutaneous formulation of Leqembi. This approval is based on the integrated results of data and associated modeling and simulation from the 18-month core study of the Phase 3 Clarity AD study of Leqembi in patients with mild cognitive impairment (MCI) due to AD or mild AD dementia (collectively referred to as early AD), as well as multiple subcutaneous administration sub-studies in its subsequent long-term extension (LTE). Once-weekly administration of the 500 mg subcutaneous formulation demonstrated similar exposure to IV administration once every two weeks and supported the expectation that the subcutaneous formulation provides efficacy comparable to that of the IV formulation. The overall safety profile of subcutaneous administration was generally similar to that of IV administration, while systemic injection/infusion-related reactions were observed less frequently with subcutaneous administration (1.4%)[2] compared with IV administration.

—

This is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person below, on September 16, 2026, at 08:05 am CEST.
 

September 3, 2026 06:00 Regulatory

Stockholm, Sweden, September 3, 2026 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the National Medical Products Administration (NMPA) of China has approved the Leqembi subcutaneous autoinjector formulation (Leqembi SC-AI) as an initiation treatment for mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) or mild AD dementia (collectively referred to as early AD).

The application was accepted by the NMPA in January 2026 and was subsequently granted Priority Review designation. Launch in China is planned during Eisai’s Fiscal Year 2026 which ends on March 31, 2027.

Leqembi SC-AI is a self-administered autoinjector formulation. The approved regimen is 500 mg given once weekly as two consecutive 250 mg injections. With this approval, Leqembi treatment now offers a new option of once-weekly SC administration at home, as an alternative to intravenous (IV) administration every two weeks in a hospital setting. Patients may also switch between IV and SC administration during treatment.

Leqembi SC-AI may significantly reduce the time required for IV infusions (approximate injection time of 15 seconds per injection). In addition, at-home administration may reduce the burden of clinic visits for patients and their care partners and enable treatment options that better fit their lifestyles. The subcutaneous treatment option is expected to lower barriers to initiating and continuing treatment. Furthermore, Leqembi SC-AI also has the potential to reduce healthcare resources associated with IV dosing, such as nurse monitoring and maintaining infusion capacity. For ARIA (amyloid-related imaging abnormalities) monitoring, as with IV administration, brain magnetic resonance imaging (MRI) is performed prior to initiating treatment and at specified time points after treatment initiation.

This marks the second country globally to approve Leqembi SC-AI. This approval is based on the integrated results of data and associated modeling and simulation from the 18-month core study of the Phase 3 Clarity AD study of Leqembi in patients with early Alzheimer’s disease, as well as multiple subcutaneous administration sub-studies (including the Chinese cohort) in its subsequent long-term extension (LTE). Once-weekly administration of SC-AI 500mg demonstrated exposure equivalent to IV administration once every two weeks, with similar clinical and biomarker outcomes. The overall safety profile of SC administration was generally similar to that of IV administration. Injection-related reactions were observed with subcutaneous Leqembi, most of which were localized, while systemic reactions were less frequently observed.

Eisai estimates that there were 17 million patients with MCI or mild dementia due to Alzheimer’s disease in China in 2024, a number that is expected to increase as the population ages. Leqembi was launched in China in June 2024.

—

This is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person below, on September 3, 2026, at 06:00 am CEST.
 

Prompts

BioArctic (ticker BIOA-B), listed in Sweden.

ETFs Holding BioArctic

ETF Weight in ETF Shares Market value As of
AVSD 0.02% 2,886 $ 88.93K Nov 16, 2026
DIHP 0.02% 34,511 $ 1.08M Nov 12, 2026
DFSI 0.01% 5,340 $ 167.075K Nov 12, 2026
AVDV 0.01% 59,815 $ 1.843M Nov 16, 2026
DXIV 0.01% 516 $ 16.144K Nov 12, 2026
DFIC 0.01% 29,738 $ 930.427K Nov 12, 2026
DFIS 0.00% 8,140 $ 254.68K Nov 12, 2026
DFAI 0.00% 24,877 $ 778.338K Nov 12, 2026
DFAX 0.00% 2,386 $ 74.652K Nov 12, 2026
AVDE 0.00% 1,540 $ 47.454K Nov 16, 2026